Aro Biotherapeutics

Executive Summary

Aro Biotherapeutics is a preclinical-stage biotechnology company pioneering Centyrin-based RNA therapeutics for genetically defined diseases, with a focus on rare and musculoskeletal disorders. The company's proprietary platform fuses a Centyrin protein scaffold (derived from fibronectin) with RNAi modalities, enabling tissue-targeted delivery to silence disease-causing genes specifically in affected cells. This approach aims to improve precision and reduce off-target effects compared to conventional RNA therapeutics, potentially unlocking safer and more effective treatments for conditions with high unmet need. Founded in 2018 and headquartered in Philadelphia, the company has raised approximately $41.5 million in funding, reflecting early investor interest in its differentiated technology. Aro's lead programs remain in preclinical development, with the most advanced candidates targeting genetic drivers of musculoskeletal and rare diseases. The company's ability to demonstrate in vivo proof-of-concept in animal models and advance toward IND-enabling studies will be critical near-term milestones. While still early-stage, Aro's platform has the potential to address limitations of existing RNA therapies by enabling cell-specific targeting, thereby broadening the therapeutic window. Successful progression through preclinical stages and securing additional financing or partnerships will be key to validating the technology and advancing toward clinical development.

Upcoming Catalysts (preview)

• TBDLead program IND/CTA filing40% success
• H2 2026Preclinical proof-of-concept data in a key indication60% success
• 2026Series B financing or partnership announcement50% success